PL409663A1 - Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia wątroby typu C (HCV) - Google Patents

Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia wątroby typu C (HCV)

Info

Publication number
PL409663A1
PL409663A1 PL409663A PL40966314A PL409663A1 PL 409663 A1 PL409663 A1 PL 409663A1 PL 409663 A PL409663 A PL 409663A PL 40966314 A PL40966314 A PL 40966314A PL 409663 A1 PL409663 A1 PL 409663A1
Authority
PL
Poland
Prior art keywords
hcv
acid esters
peptide derivatives
aminalkyl
inhibitors
Prior art date
Application number
PL409663A
Other languages
English (en)
Other versions
PL227285B1 (pl
Inventor
Marcin Skoreński
Monika Besman
Marcin Sieńczyk
Józef Oleksyszyn
Original Assignee
Politechnika Wrocławska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Wrocławska filed Critical Politechnika Wrocławska
Priority to PL409663A priority Critical patent/PL227285B1/pl
Priority to PCT/IB2015/054670 priority patent/WO2016051289A1/en
Publication of PL409663A1 publication Critical patent/PL409663A1/pl
Publication of PL227285B1 publication Critical patent/PL227285B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Wynalazek dotyczy zastosowania peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych o wzorze ogólnym I w którym (W) oznacza podstawnik Boc-Val-Pro lub Cbz-Val-Pro, (R) oznacza pierścień fenylowy podstawiony w pozycji para grupą X, która oznacza: wodór, grupę S-metylową, grupę O-metylową, chlor lub podstawnik 2,2,3,3-tetrafluoropropanowy jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia wątroby typu C (HCV).
PL409663A 2014-10-02 2014-10-02 Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia watroby typu C (HCV) PL227285B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL409663A PL227285B1 (pl) 2014-10-02 2014-10-02 Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia watroby typu C (HCV)
PCT/IB2015/054670 WO2016051289A1 (en) 2014-10-02 2015-06-22 Antiviral pharmaceutical preparation for use in treatment of hepatitis c

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL409663A PL227285B1 (pl) 2014-10-02 2014-10-02 Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia watroby typu C (HCV)

Publications (2)

Publication Number Publication Date
PL409663A1 true PL409663A1 (pl) 2015-06-22
PL227285B1 PL227285B1 (pl) 2017-11-30

Family

ID=53396838

Family Applications (1)

Application Number Title Priority Date Filing Date
PL409663A PL227285B1 (pl) 2014-10-02 2014-10-02 Zastosowanie peptydowych pochodnych estrów kwasów 1-aminoalkilofosfonowych jako inhibitorów proteazy NS3/4A ekspresjonowanej przez ludzki wirus zapalenia watroby typu C (HCV)

Country Status (2)

Country Link
PL (1) PL227285B1 (pl)
WO (1) WO2016051289A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66213B1 (sr) * 2021-04-16 2024-12-31 Fujian Akeylink Biotechnology Co Ltd Jedinjenje kratkog peptida prolina modifikovanog prstenom i upotreba istog

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232527A1 (en) 2005-06-02 2007-10-04 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20120158515A1 (en) 2010-12-21 2012-06-21 Yahoo! Inc. Dynamic advertisement serving based on an avatar

Also Published As

Publication number Publication date
PL227285B1 (pl) 2017-11-30
WO2016051289A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
EA201792021A1 (ru) Ингибитор jak
PH12018500931A1 (en) Hcv polymerase inhibitors
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
GEAP202115353A (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
EA201491361A1 (ru) Ингибиторы вируса гепатита c
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
GEP20176800B (en) D-amino acid compounds for liver disease
NZ727392A (en) Methods of preparing substituted nucleotide analogs
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
PH12019501362B1 (en) Polymorphs
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
DOP2013000017A (es) Procesos para preparar compuestos antivirales
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
PH12020550947A1 (en) Polymorphs
MX379859B (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
EA201790098A1 (ru) Гербицидно действующие амиды арилкарбоновых кислот
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων